These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 21326082

  • 21. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 22. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Riddle MC, Schneider J.
    Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
    [Abstract] [Full Text] [Related]

  • 23. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR.
    Diabetes Obes Metab; 2013 Mar; 15(3):204-12. PubMed ID: 22985213
    [Abstract] [Full Text] [Related]

  • 24. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 25. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S, Hariharan RS, Madhavan R, Periyandavar I, Samra SS.
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [Abstract] [Full Text] [Related]

  • 26. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.
    Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S.
    Diabet Med; 2001 Oct; 18(10):828-34. PubMed ID: 11678974
    [Abstract] [Full Text] [Related]

  • 27. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S, Saxena GN, Keshwani P, Gupta R.
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [Abstract] [Full Text] [Related]

  • 28. Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
    Rubin CJ, Ledeine JM, Fiedorek FT.
    Diab Vasc Dis Res; 2008 Sep; 5(3):168-76. PubMed ID: 18777489
    [Abstract] [Full Text] [Related]

  • 29. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Moon JS, Ha KS, Yoon JS, Lee HW, Lee HC, Won KC, BETA study group.
    Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
    [Abstract] [Full Text] [Related]

  • 30. The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.
    Kazda C, Gallwitz B, Simó R, Guzmán JR, Kraus P, Nicolay C, Rose L, Schernthaner G.
    Diabetes Obes Metab; 2009 Dec; 11(12):1131-7. PubMed ID: 19758357
    [Abstract] [Full Text] [Related]

  • 31. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
    Mokta JK, Ramesh, Sahai AK, Kaundal PK, Mokta K.
    J Assoc Physicians India; 2018 Aug; 66(8):30-35. PubMed ID: 31324081
    [Abstract] [Full Text] [Related]

  • 32. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.
    Kabadi UM, Kabadi M.
    Diabetes Res Clin Pract; 2006 Jun; 72(3):265-70. PubMed ID: 16406190
    [Abstract] [Full Text] [Related]

  • 33. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.
    Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
    [Abstract] [Full Text] [Related]

  • 34. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [Abstract] [Full Text] [Related]

  • 35. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Schernthaner G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B.
    Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
    [Abstract] [Full Text] [Related]

  • 36. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
    Lewin A, Lipetz R, Wu J, Schwartz S.
    Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
    [Abstract] [Full Text] [Related]

  • 37. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
    Shin Y, Moon JH, Chin HJ, Ferrannini E, Lim S.
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
    [Abstract] [Full Text] [Related]

  • 38. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS, Shin JA, Lee SH, Kim ES, Cho JH, Son HY, Yoon KH.
    Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
    [Abstract] [Full Text] [Related]

  • 39. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
    Rosenstock J, Samols E, Muchmore DB, Schneider J.
    Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
    [Abstract] [Full Text] [Related]

  • 40. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.